MedDataX Logo

A Registry Study on Primary/idiopathic Triglyceride Deposit Cardiomyovasculopathy

NCT ID: NCT05345223

Last Updated: 2024-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

193 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-31

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to construct a registry; in order to understand the onset status of triglyceride deposit cardiomyovasculopathy (TGCV) in Japan with patients' background and natural history of the disease, and to explore disease-specific prognostic factors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Triglyceride Deposit Cardiomyovasculopathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

triglyceride deposit cardiomyovasculopathy TGCV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TGCV

Patients who have been confirmed as TGCV by a cardiologist.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients who have been confirmed as TGCV based on the diagnostic criteria for TGCV

Exclusion Criteria

* The patients who refused to participate in the study by opt-out
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Osaka University Graduate School of Medicine

UNKNOWN

Sponsor Role collaborator

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ken-ichi Hirano, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Triglyceride Science, Graduate School of Medicine, Osaka University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aichi Medical University

Nagakute, Aichi-ken, Japan

Site Status

Nagoya University

Nagoya, Aichi-ken, Japan

Site Status

Chiba University Graduate School of Medicine

Chiba, Chiba, Japan

Site Status

Kyushu University

Fukuoka, Fukuoka, Japan

Site Status

Hyogo Medical University

Nishinomiya, Hyōgo, Japan

Site Status

Osaka University Hospital

Suita, Osaka, Japan

Site Status

Juntendo University

Bunkyo, Tokyo, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20334(T2)-3

Identifier Type: -

Identifier Source: org_study_id